Daiichi Sankyo plans €1B expansion to enhance Antibody-Drug Conjugate production in Germany

CAR-T Digest - August 2020

20 Feb 2024: Daiichi Sankyo plans €1B expansion to enhance Antibody-Drug Conjugate production in Germany

Daiichi Sankyo unveils a €1 billion expansion plan to bolster antibody-drug conjugate (ADC) production in Germany, aiming to establish an “international innovation center” for future ADC development
The expansion, set to be completed by 2030, will create at least 350 new jobs and equip the site to develop and manufacture ADCs targeting breast, lung, and stomach cancers
This investment marks a strategic move by Daiichi to dominate the rapidly growing ADC field, positioning itself as a key player in oncological therapies
The investment reflects the company’s dedication to innovation and quality, positioning it to lead in the increasingly competitive biopharmaceutical landscape